HOA Puts into Operation of Updated CyberKnife Version
Cancer patients now have a solid reason to cheer, as US-based Hematology-Oncology Associates (HOA) lately came up with the new CyberKnife (CK) and replaced their original CyberKnife with an updated that is even more precise, fast and effective, and known as the CyberKnife M6 Series that has remarkable pain relief. The new CyberKnife (CK) is the only FDA approved completely Robotic Stereotactic Radiosurgery System available in the world that targets and destroys previously inaccessible tumors. The CyberKnife M6 Series model is endowed with the notable feature of delivering doses with sub-millimeter accuracy, to both static as well as moving targets. Its radiation dose adjusts automatically in the real-time to respiration as well as other changes in tumor position. Moreover, the updated version of the robotic radiosurgery system has anatomy-specific tracking and treatment delivery solutions for brain, spine, lung and prostate. It has become a standard option for prostate cancer treatment and unlike conventional radiation/IMRT, only the CyberKnife has a five-day treatment regime instead of a 45-day treatment regime for prostate cancer. It cuts down on co-pays and the overall costs of treating prostate cancer. In addition, over 9 years of data shows profiles on sparing healthy tissues, namely rectum and bladder, to be better than IMRT when the CyberKnife was used for prostate treatment. In essence, the CyberKnife mode of cancer treatment proves to be higher in efficacy and at the same time reduces the treatment time.